Lack of cross-reactivity between cefotaxime and imipenem

Lack of cross-reactivity between cefotaxime and imipenem

Bibliographic Details
Main Authors:	K Aouam, C Loussaief, M Chakroun, NA Boughattas, N Bouzouaia, Romdhane Ben
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2006-03-01
Series:	Swiss Medical Weekly
Subjects:	Imipenem Cefotaxime
Online Access:	https://www.smw.ch/index.php/smw/article/view/579

Similar Items

Chromatographic analysis of immobilized cefotaxime
by: Stirbet Daniela, et al.
Published: (2014-01-01)

Rifaximin plus cefotaxime versus cefotaxime alone in treatment of spontaneous bacterial peritonitis in patients with cirrhosis
by: Asmaa N Mohammad, et al.
Published: (2018-01-01)

Clinical Pharmacology of Cefotaxime in Neonates and Infants: Effects and Pharmacokinetics
by: Gianmaria Pacifici, et al.
Published: (2017-11-01)

Ampicillin-Gentamycin Were Equivalent to Cefotaxime-Gentamycin Therapy Outcome on Neonatal Sepsis in Rural Area of West Borneo
by: Amelia Handoko, et al.
Published: (2022-06-01)

Formulation and Evaluation of Cefotaxime Sodium Loaded Emulgel for Topical Bacterial Infections
by: Esra Tariq Anwer, et al.
Published: (2022-12-01)

Cefotaxime Loaded Polycaprolactone Based Polymeric Nanoparticles with Antifouling Properties for In-Vitro Drug Release Applications
by: Sana Javaid, et al.
Published: (2021-06-01)

Cefotaxime-induced inspissated bile syndrome in a newborn: A case report
by: Fareeda Galley, et al.
Published: (2024-02-01)

Microspheres with 2D rGO/Alginate Matrix for Unusual Prolonged Release of Cefotaxime
by: Islam Gomaa, et al.
Published: (2023-05-01)

Comparison of Cefuroxim versus Cefotaxim in the Treatment of Pneumonia in Children Aged 3 Months- 5 Years an Imaging and Clinical Examination Evidence: Randomized Controlled Trial.
by: Hashem Mohammed Mansour, et al.
Published: (2014-09-01)

Low Release Study of Cefotaxime by Functionalized Mesoporous Silica Nanomaterials
by: Dan Eduard Mihaiescu, et al.
Published: (2022-11-01)

Colonization Dynamics of Cefotaxime Resistant Bacteria in Beef Cattle Raised Without Cephalosporin Antibiotics
by: Raies A. Mir, et al.
Published: (2018-03-01)

Direct Colorimetry of Imipenem Decomposition as a Novel Cost-Effective Method for Detecting Carbapenemase-Producing Enterobacteria
by: Stathis D. Kotsakis, et al.
Published: (2022-08-01)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
by: Mervat Mashaly, et al.
Published: (2022-02-01)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
by: Soo Min Jang, et al.
Published: (2021-09-01)

Optimal dose of cefotaxime in neonates with early-onset sepsis: A developmental pharmacokinetic model-based evaluation
by: Zhen-Hai Shang, et al.
Published: (2022-09-01)

Cefotaxime Mediated Synthesis of Gold Nanoparticles: Characterization and Antibacterial Activity
by: Turki Al Hagbani, et al.
Published: (2022-02-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
by: I. I. Shteynberg, et al.
Published: (2015-03-01)

Antimicrobial use and detection of cefotaxime-resistant Enterobacteriaceae in the pig production chain, Ogun State, Nigeria
by: O.E. Ojo, et al.
Published: (2020-11-01)

Drug Utilization Evaluation of Imipenem in Patients Undergoing Bone Marrow Transplantation
by: Elnaz Sakhaiyan, et al.
Published: (2009-04-01)

Drug Utilization Evaluation of Imipenem in Patients Undergoing Bone Marrow Transplantation
by: Elnaz Sakhaiyan, et al.
Published: (2009-06-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
by: Hiroki Nakamura, et al.
Published: (2024-03-01)

Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa
by: Caterina Ferretti, et al.
Published: (2024-06-01)

Cefotaxime/sulbactam: clinical and pharmacological characteristics
by: Ortenberg E.A., et al.
Published: (2019-12-01)

Drug Utilization Evaluation of Imipenem and Assessing the Role of Pharmacist Interventions
by: Neda Farzadi, et al.
Published: (2020-09-01)

Prevalence and molecular characterization of cefotaxime-resistant Salmonella strains recovered from retail meat samples in Shenzhen, China, during 2014–2017
by: Chen Yang, et al.
Published: (2023-10-01)

Exploiting of Green Synthesized Metal Oxide Nanoparticles for Spectrophotometric Determination of Levofloxacin, Cephalexin, and Cefotaxime Sodium in Commercial Products
by: Nawal Ahmed Alarfaj, et al.
Published: (2021-04-01)

Occurrence of blaOXA-23 gene in imipenem-susceptible Acinetobacter baumannii
by: Karyne Rangel Carvalho, et al.
Published: (2011-06-01)

<i>Pseudomonas aeruginosa</i> Response to Acidic Stress and Imipenem Resistance
by: Faraz Ahmed, et al.
Published: (2022-08-01)

Green Chemometric Determination of Cefotaxime Sodium in the Presence of Its Degradation Impurities Using Different Multivariate Data Processing Tools; GAPI and AGREE Greenness Evaluation
by: Yasmine Ahmed Sharaf, et al.
Published: (2023-02-01)

The Effects of Colistin on Imipenem MICs in OXA-48 Producing Klebsiella pneumoniae Isolates: An In Vitro Study
by: Yücel DUMAN, et al.
Published: (2021-12-01)

In Vitro Microevolution and Co-Selection Assessment of Amoxicillin and Cefotaxime Impact on <i>Escherichia coli</i> Resistance Development
by: Ádám Kerek, et al.
Published: (2024-03-01)

Unveiling the Role of Nonionic Surfactants in Enhancing Cefotaxime Drug Solubility: A UV-Visible Spectroscopic Investigation in Single and Mixed Micellar Formulations
by: Aysha Arshad Rana, et al.
Published: (2023-11-01)

Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients
by: Femke de Velde, et al.
Published: (2021-12-01)

Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia
by: Sutep Jaruratanasirikul, et al.
Published: (2015-02-01)

Assessment of The Imipenem Antibiotic Effects on The Expression of Staphylococcus Saprophyticus Serine-Aspartate Repeat Protein-Encoding Genes Isolated from Clinical Cases
by: Afsaneh Abedin, et al.
Published: (2021-11-01)

Machine learning model of imipenem‐resistant Klebsiella pneumoniae based on MALDI‐TOF‐MS platform: An observational study
by: Yu Zeng, et al.
Published: (2023-09-01)

Detection of aztreonam, meropenem and imipenem resistant Gram negative bacteria from inpatient department in Federal Medical Center (FMC), Birnin, Kebbi, Nigeria
by: Bilyaminu Jega, et al.
Published: (2024-02-01)

Comparison of In Vitro Activity of Ceftazidime-Avibactam and Imipenem-Relebactam against Clinical Isolates of Pseudomonas aeruginosa
by: Leilei Wang, et al.
Published: (2023-06-01)

Ceftazidime–Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing <i>Klebsiella pneumoniae</i>
by: Li Ding, et al.
Published: (2022-04-01)

Model-Informed Precision Dosing of Imipenem in an Obese Adolescent Patient with Augmented Renal Clearance and History of Schizophrenia
by: Chen Y, et al.
Published: (2024-02-01)